Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2Sarcoma 1

Conditions

Myelodysplastic Syndromes 58Leukemia 56Leukemia, Myeloid, Acute 47Lymphoma 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 37Lymphoma, Non-Hodgkin 35Leukemia, Lymphocytic, Chronic, B-Cell 35Myeloproliferative Disorders 34Multiple Myeloma 31Hodgkin Disease 30Leukemia, Myeloid, Chronic-Phase 28Leukemia, Myeloid, Accelerated Phase 28Lymphoma, Follicular 27Lymphoma, B-Cell, Marginal Zone 27Burkitt Lymphoma 27Lymphoma, Large B-Cell, Diffuse 26Lymphoma, Mantle-Cell 25Neoplasms, Plasma Cell 24Leukemia, Myelomonocytic, Chronic 23Congenital Abnormalities 23Lymphoma, Large-Cell, Immunoblastic 22Myelodysplastic-Myeloproliferative Diseases 20Graft vs Host Disease 20Blast Crisis 20Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 19Anemia, Refractory, with Excess of Blasts 19Primary Myelofibrosis 18Dendritic Cell Sarcoma, Interdigitating 18Recurrence 17Hematologic Neoplasms 16

Interventions

Dexamethasone 6fludarabine 5Whole-Body Irradiation 5Mycophenolic Acid 5Melphalan 5Lenalidomide 5Cyclophosphamide 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Tacrolimus 3Calcium Dobesilate 3Bortezomib 3dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Stem Cell Transplantation 2Sirolimus 2Antilymphocyte Serum 2Allopurinol 2pomalidomide 1plerixafor 1pegylated granulocyte colony-stimulating factor 1liposomal doxorubicin 1ixazomib 1isatuximab 1ferric pyrophosphate 1elotuzumab 1carmustine, poliferprosan 20 drug combination 1carfilzomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Plasma Cell × Antilymphocyte Serum × Clear all
NCT02722668 2025-07-04

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
15 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cellSarcoma

Bone Marrow Failure Disorders, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Leukemia, Plasma Cell, Lymphoma, Follicular, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Primary Myelofibrosis

NCT02661035 2023-09-21

Allo HSCT Using RIC for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
156 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hematologic Diseases, Leukemia, Plasma Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡